BAM
HAE icon

Byrne Asset Management’s Haemonetics HAE Stock Holding History

Byrne Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-858
Closed -$41.8K – 588
2025
Q3 		$41.8K Buy
+858
New +$53.1K 0.03% 270
2024
Q2 		– Sell
-220
Closed -$18.8K – 543
2024
Q1 		$18.8K Buy
+220
New +$17.3K 0.01% 305
2023
Q2 		– Sell
-305
Closed -$25K – 605
2023
Q1 		$25K Buy
305
+119
+64% +$9.63K 0.02% 287
2022
Q4 		$14.6K Buy
+186
New +$14.9K 0.01% 348

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Byrne Asset Management's HAE Position: Q4 2025 in Review

Byrne Asset Management sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 858 shares — an estimated $41.8K sold.

Byrne Asset Management first reported a position in HAE in Q4 2022 and held it in 4 quarters. The position peaked at $41.8K in Q3 2025. 328 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Byrne Asset Management reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Byrne Asset Management sold 858 Haemonetics shares in Q4 2025, an estimated $41.8K.
  • Byrne Asset Management first reported a position in Haemonetics in Q4 2022 and held it in 4 quarters.
  • Byrne Asset Management's Haemonetics position peaked at $41.8K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Byrne Asset Management's 13F filing for Q4 2025, filed 12 Jan 2026.